The positive Phase 2 preeclampsia data and upcoming FGR topline results in September are the primary near-term catalysts. Traders should watch for the KOL call in September and the ReMEDy2 interim analysis in early 2027, which are the next major binary events. The cash runway through 2027 removes near-term financing risk.
Price Chart
Executive Summary
DiaMedica reported Q2 2026 EPS of -$0.19, a 5% beat vs. the -$0.20 consensus, but net loss widened to $10.1M from $7.7M YoY as R&D spend increased. The key catalyst is the positive Phase 2 Part 1a topline data for DM199 in preeclampsia, showing statistically significant blood pressure reductions, and the completion of enrollment in the first FGR cohort. Cash runway through 2027 and the upcoming ReMEDy2 interim analysis in early 2027 provide a clear pipeline catalyst, making this a clinical-stage event-driven read rather than a financial one.
Key Financial Metrics
Key Facts
- Positive Phase 2 Part 1a topline results: DM199 produced a mean 29.1 mmHg reduction in SBP (p<0.001) and 17.0 mmHg reduction in DBP (p<0.001) in late-onset preeclampsia.
- Enrollment complete in first cohort (6 patients) of Phase 2 early-onset FGR trial; KOL call and topline results expected in September.
- ReMEDy2 AIS trial surpassed 85% of required enrollment for interim analysis; readout now expected in early 2027.
- Health Canada authorized the global Phase 2 early-onset preeclampsia study; first patient dosing expected Q4 2026.
- Cash, cash equivalents and short-term investments were $43.5M as of June 30, 2026, with runway through 2027.
- Net loss for Q2 2026 was $10.1M, up from $7.7M in Q2 2025, driven by increased R&D spending.
Financial Impact
Net loss of $10.1M in Q2 2026 vs $7.7M in Q2 2025; cash burn of $17.2M in H1 2026 vs $14.7M in H1 2025; cash position of $43.5M provides runway through 2027.
Risk Factors
- Clinical trial failure in ongoing or future studies (FGR, early-onset PE, ReMEDy2).
- Regulatory delays or negative feedback from FDA on the U.S. IND pathway for preeclampsia.
- Dilution risk if the company needs to raise capital beyond current runway.
- Competition from existing and pipeline therapies for preeclampsia and stroke.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-026790 |
| Document: dmtp20260809_8k.htm | 0001437749-26-026790 |
| Document: 0001437749-26-026790-index-headers.html | 0001437749-26-026790 |
| Document: 0001437749-26-026790-index.html | 0001437749-26-026790 |
| Document: 0001437749-26-026790.txt | 0001437749-26-026790 |
| 8-K Data (Synthetic) | 0001437749-26-026790 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $6.62 $6.53 | ▼ −1.36% | ▲ +0.62% | $8.39 (+26.74%) |
Aug 10, 2026 11w ago | 8-K | $6.87 $6.59 | ▼ −4.08% | ▼ −3.02% | $8.39 (+22.13%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.46 $7.71 | ▲ +41.21% | ▲ +39.32% | $8.39 (+53.66%) |
May 6, 2026 24w ago | 8-K | $6.53 $5.65 | ▲ +13.48% | ▲ +16.61% | $8.39 (−28.48%) |
Apr 1, 2026 29w ago | DEFA14A | $6.48 $6.05 | ▼ −6.64% | ▼ −16.51% | $8.39 (+29.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers